Imprimis Pharmaceuticals

Acadia Pharmaceutical is a biopharmaceutical company based in San Diego, California, specializing in the development of innovative treatments for neurological and central nervous system disorders. With a focus on research and clinical trials, Acadia Pharmaceutical is committed to advancing medical science and improving the lives of patients through cutting-edge pharmaceutical solutions. Generated from their business information

Acadia Pharmaceuticals, based in San Diego, CA, is a pioneering company at the forefront of neuroscience breakthroughs, dedicated to elevating life. With over 25 years of experience, Acadia is committed to providing vital solutions to address unmet medical needs. Their FDA-approved treatments, including NUPLAZID for Parkinson's Disease Psychosis and DAYBUE for Rett syndrome, have revolutionized the field, while their ongoing clinical-stage developments focus on addressing negative symptoms in schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, and neuropsychiatric symptoms in CNS disorders. Driven by a mission to fight diseases and ensure a brighter future for all, Acadia is united in their commitment to elevating life. They embrace diverse perspectives, foster collaboration, and stand resilient in their dedication to developing innovative therapies in areas with high unmet needs. With a focus on patient support, education, and connection, Acadia goes beyond therapies to help patients in their fight against diseases.Generated from the website

Ligand Pharmaceuticals Inc., based in San Diego, CA, is a specialist in healthcare investing, focusing on the clinical development and commercialization of high-value medicines. The company boasts one of the largest and most diverse portfolios of biopharmaceutical royalties, featuring over 90 partnered commercial and development stage programs across various disease areas, including cancer and rare conditions. In addition to its royalty portfolio, Ligand maintains and licenses its proprietary technology platforms, Captisol and NITRICIL, to a wide network of biopharmaceutical partners, including major pharmaceutical manufacturers globally. The company's economic rights extend to more than 30 commercial programs marketed in over 70 countries, illustrating its significant impact in advancing tomorrow's medicines through technology and financial solutions. Generated from the website